› Forums › General Melanoma Community › Melanoma and BRAF
- This topic has 3 replies, 4 voices, and was last updated 9 months, 1 week ago by edwardkim.
- Post
-
- July 22, 2023 at 11:20 am
After my biopsy was done, the report noted:Left neck lymph node was biopsied under ultrasound on 6/12/2023. The
results showed melanoma (SOX10 strongly positive, melan A strongly positiveI had specifically asked about what “markers” my melanoma showed, and this was it.
But yesterday I asked specifically about the BRAF/V600E mutation, as many papers and articles
refer to it with respect to treatment options.
I was shocked that my major cancer center told me: we didn’t check for that, but we will and
we will let you know.Does this make sense?
Am I wrong about whether knowing this is important?
Am I wrong in thinking they should have already known this?Thanks,
FinemRespice
Viewing 2 reply threads
- Replies
-
-
- July 24, 2023 at 8:56 pm
I believe that information only comes from genetic testing and takes some time to process. It does not happen automatically, everywhere and often depends on insurance. It may not be automatic so you may need to confirm that it was done. At the very least, it will not be information that is immediately available. -
- July 25, 2023 at 5:52 pm
Finem, SOX10 and MELAN A are part of immunohistochemistry test that look at tissue from surgery tissue/biopsy using stains added to slice of tissue and then look under the microscope to see if tissue is melanoma or not. Following article gets into the testing of tissue. BRAF mutation status of being positive or negative does not make difference in first line treatment setting these days as Immunotherapy treatments have proven via clinical trials to be best starting point. If your tumor turns out to be BRAF+ then you have option if immunotherapy does not work of switching to targeted therapy drugs like BRAFTovi and MEKTovi ( there are two other drug pills combination to pick from).https://pubmed.ncbi.nlm.nih.gov/25356946/
-
Viewing 2 reply threads
- You must be logged in to reply to this topic.